Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
<p>Abstract</p> <p>Background</p> <p>Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer. The purpose of this study was to identify the clinical significance of potential predictive and prog...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-11-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/7/203 |
| _version_ | 1819033926516080640 |
|---|---|
| author | Kim Dong-Wan Han Wonshik Chie Eui Lee Se-Hoon Kim Jee Oh Do-Youn Kim Hee-Jun Im Seock-Ah Keam Bhumsuk Moon Woo Kim Tae-You Park In Noh Dong-Young Heo Dae Ha Sung Bang Yung-Jue |
| author_facet | Kim Dong-Wan Han Wonshik Chie Eui Lee Se-Hoon Kim Jee Oh Do-Youn Kim Hee-Jun Im Seock-Ah Keam Bhumsuk Moon Woo Kim Tae-You Park In Noh Dong-Young Heo Dae Ha Sung Bang Yung-Jue |
| author_sort | Kim Dong-Wan |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer. The purpose of this study was to identify the clinical significance of potential predictive and prognostic factors in breast cancer patients treated by neoadjuvant chemotherapy.</p> <p>Methods</p> <p>A total of 145 stage II and III breast cancer patients received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. We examined the clinical and biological factors (ER, PR, p53, c-erbB2, bcl-2, and Ki-67) by immunohistochemistry. We analyzed clinical outcome and their correlation with clinicopathologic parameters.</p> <p>Results</p> <p>Among the clinicopathologic parameters investigated, none of the marker was correlated with response rate (RR) except triple negative phenotype. Patients with triple negative phenotype showed higher RR (83.0% in triple negative <it>vs</it>. 62.2% in non-triple negative, <it>p </it>= 0.012) and pathologic complete RR (17.0% in triple negative <it>vs</it>. 3.1% in non-triple negative, <it>p </it>= 0.005). However, relapse free survival (RFS) and overall survival (OS) were significantly shorter in triple negative breast cancer patients (<it>p </it>< 0.001, <it>p </it>= 0.021, respectively). Low histologic grade, positive hormone receptors, positive bcl-2 and low level of Ki-67 were associated with prolonged RFS. In addition, positive ER and positive bcl-2 were associated with prolonged OS. In our homogeneous patient population, initial clinical stage reflects RFS and OS more precisely than pathologic stage. In multivariate analysis, initial clinical stage was the only significant independent prognostic factor to impact on OS (hazard ratio 3.597, <it>p </it>= 0.044).</p> <p>Conclusion</p> <p>Several molecular markers provided useful predictive and prognostic information in stage II and III breast cancer patients treated with neoadjuvant docetaxel/doxorubicin chemotherapy. Triple negative phenotype was associated with shorter survival, even though it was associated with a higher response rate to neoadjuvant chemotherapy.</p> |
| first_indexed | 2024-12-21T07:25:36Z |
| format | Article |
| id | doaj.art-1eafcac782cc4fdfb9f07e136dada982 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-21T07:25:36Z |
| publishDate | 2007-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-1eafcac782cc4fdfb9f07e136dada9822022-12-21T19:11:41ZengBMCBMC Cancer1471-24072007-11-017120310.1186/1471-2407-7-203Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancerKim Dong-WanHan WonshikChie EuiLee Se-HoonKim JeeOh Do-YounKim Hee-JunIm Seock-AhKeam BhumsukMoon WooKim Tae-YouPark InNoh Dong-YoungHeo DaeHa SungBang Yung-Jue<p>Abstract</p> <p>Background</p> <p>Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer. The purpose of this study was to identify the clinical significance of potential predictive and prognostic factors in breast cancer patients treated by neoadjuvant chemotherapy.</p> <p>Methods</p> <p>A total of 145 stage II and III breast cancer patients received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. We examined the clinical and biological factors (ER, PR, p53, c-erbB2, bcl-2, and Ki-67) by immunohistochemistry. We analyzed clinical outcome and their correlation with clinicopathologic parameters.</p> <p>Results</p> <p>Among the clinicopathologic parameters investigated, none of the marker was correlated with response rate (RR) except triple negative phenotype. Patients with triple negative phenotype showed higher RR (83.0% in triple negative <it>vs</it>. 62.2% in non-triple negative, <it>p </it>= 0.012) and pathologic complete RR (17.0% in triple negative <it>vs</it>. 3.1% in non-triple negative, <it>p </it>= 0.005). However, relapse free survival (RFS) and overall survival (OS) were significantly shorter in triple negative breast cancer patients (<it>p </it>< 0.001, <it>p </it>= 0.021, respectively). Low histologic grade, positive hormone receptors, positive bcl-2 and low level of Ki-67 were associated with prolonged RFS. In addition, positive ER and positive bcl-2 were associated with prolonged OS. In our homogeneous patient population, initial clinical stage reflects RFS and OS more precisely than pathologic stage. In multivariate analysis, initial clinical stage was the only significant independent prognostic factor to impact on OS (hazard ratio 3.597, <it>p </it>= 0.044).</p> <p>Conclusion</p> <p>Several molecular markers provided useful predictive and prognostic information in stage II and III breast cancer patients treated with neoadjuvant docetaxel/doxorubicin chemotherapy. Triple negative phenotype was associated with shorter survival, even though it was associated with a higher response rate to neoadjuvant chemotherapy.</p>http://www.biomedcentral.com/1471-2407/7/203 |
| spellingShingle | Kim Dong-Wan Han Wonshik Chie Eui Lee Se-Hoon Kim Jee Oh Do-Youn Kim Hee-Jun Im Seock-Ah Keam Bhumsuk Moon Woo Kim Tae-You Park In Noh Dong-Young Heo Dae Ha Sung Bang Yung-Jue Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer BMC Cancer |
| title | Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer |
| title_full | Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer |
| title_fullStr | Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer |
| title_full_unstemmed | Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer |
| title_short | Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer |
| title_sort | prognostic impact of clinicopathologic parameters in stage ii iii breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy paradoxical features of the triple negative breast cancer |
| url | http://www.biomedcentral.com/1471-2407/7/203 |
| work_keys_str_mv | AT kimdongwan prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT hanwonshik prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT chieeui prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT leesehoon prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT kimjee prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT ohdoyoun prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT kimheejun prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT imseockah prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT keambhumsuk prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT moonwoo prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT kimtaeyou prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT parkin prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT nohdongyoung prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT heodae prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT hasung prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer AT bangyungjue prognosticimpactofclinicopathologicparametersinstageiiiiibreastcancertreatedwithneoadjuvantdocetaxelanddoxorubicinchemotherapyparadoxicalfeaturesofthetriplenegativebreastcancer |